StockWatch
·

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Q2 FY26 Results

PACBQ2 FY26 Results
Filing
MetricValue ($ M)Q1 FY26Q2 FY25
Revenue39.014.9%1.9%
Total Income39.014.9%1.9%
Expenditure83.6283.6%1.2%
PBT-44.68452.3%6.6%
Net Profit-44.74440.3%6.7%
OPM—
NPM—
EPS-0.14366.7%0.0%
View full financials

PacBio Announces Second Quarter 2026 Financial Results

06 Aug 2026 · 6 Aug, 2:02 am

Summary

Pacific Biosciences of California, Inc. reported second quarter 2026 total revenue of $39.0 million, a slight decrease year-over-year. While consumable revenue saw an increase, instrument revenue declined. The company experienced a decrease in both GAAP and non-GAAP gross margins. The GAAP net loss for the quarter was $44.7 million. Looking ahead, PacBio anticipates full-year 2026 revenue to be between $155 million and $165 million.

Key Highlights

  1. 1

    Total revenue for the second quarter of 2026 was $39.0 million, a slight decrease from $39.8 million in the second quarter of 2025.

  2. 2

    Consumable revenue increased to $20.1 million in Q2 2026 from $18.9 million in Q2 2025.

  3. 3

    Instrument revenue was $12.8 million in Q2 2026, down from $14.2 million in Q2 2025.

  4. 4

    GAAP gross margin for Q2 2026 was 32%, compared to 37% in Q2 2025.

  5. 5

    Non-GAAP gross margin was 36% for Q2 2026, down from 38% in Q2 2025.

  6. 6

    GAAP net loss for Q2 2026 was $44.7 million, compared to $41.9 million in Q2 2025.

  7. 7

    PacBio expects full-year 2026 revenue to be in the range of $155 million to $165 million.

Management Comments

M

Mark Van Oene

I am honored to have the opportunity to lead PacBio at such an exciting time in the company's evolution, especially as we continue our pivot into further supporting the clinical markets and developing AI-related product solutions and clinically relevant databases. PacBio has built an industry-leading technology platform, an incredibly talented team, and a passionate customer community that is driving scientific and clinically important discoveries around the world. I am grateful to Christian for his leadership, mentorship, and partnership over the past several years. His vision and dedication have positioned PacBio for a tremendous future, and I look forward to building on that strong foundation. As we look ahead, we remain focused on delivering innovative sequencing solutions that enable our customers to answer some of biology's most important questions, expanding adoption of HiFi sequencing worldwide, executing with operational excellence, increasing our support of the clinical and diagnostics markets, and playing a leading role in developing AI-related HiFi sequencing solutions and databases, all as part of our continuing effort to create long-term value for our stockholders.

C

Christian Henry

It has been an extraordinary privilege to serve as PacBio's President and Chief Executive Officer and to work alongside such an exceptional team. Together, we have transformed the company, introduced groundbreaking innovations, expanded our customer base and commercial capabilities, and strengthened our position in the scientific and clinical research markets as a leader in highly accurate long-read sequencing. I am incredibly proud of what we have accomplished. Mark has been an outstanding partner since joining PacBio. He brings exceptional operational expertise, strategic vision, and a deep commitment to our customers and employees. I have complete confidence that he is the right leader to guide PacBio into its next chapter, and I look forward to a continued partnership with Mark, both as an employee during this transition period, and as a member of the Board, as he implements his strategy and vision to advance the company’s mission under his leadership.

J

John Milligan

Mark is an accomplished leader with deep experience building and scaling global life sciences and clinical diagnostic businesses, which has become an increasing focus of PacBio’s long-term strategy. Over the past several years, he has become an integral member of PacBio's leadership team and has helped shape our strategic priorities, strengthen our operational capabilities, and position the company for its next phase of growth, particularly with respect to AI-enabled product solutions and larger-scale AI and clinical related collaborations. The Board conducted a thoughtful succession planning process and unanimously concluded that Mark is the right leader to build on PacBio's strong foundation and drive long-term value creation for our customers, employees, and stockholders. On behalf of the Board, I also want to express our sincere gratitude to Christian for his outstanding leadership and many contributions to PacBio. During his tenure, Christian guided the company through a period of significant transformation, including expanding our product portfolio, strengthening our commercial organization, advancing our technology leadership, and positioning PacBio to pursue substantial long-term growth opportunities, especially in clinical and AI-related markets. We thank him for his unwavering commitment to PacBio and wish him continued success.

Informational and educational content only. Not investment advice.